These insights collectively indicate that Src inhibition could serve as a therapeutic strategy to prevent YAP-driven fibrotic responses and potentially modulate IOP in glaucoma by limiting YAP’s transcriptional activation in fibrotic pathways. Here, SRC is linked to glaucoma.